John Allan, MD

Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma at the 66th American Society of Hematology Annual Meeting and Exposition 2024.

John Allan, MD, provides insights on novel agents and treatment strategies currently being studied in chronic lymphocytic leukemia.

An expert hematologist-oncologist offers advice for community oncologists who are treating patients with newly diagnosed chronic lymphocytic leukemia.

An overview of assessing risk of disease recurrence, steps taken to minimize recurrence, and when to consider second-line treatment for patients with CLL.

An expert on CLL reviews recent data updates from studies of BTK inhibitors in the frontline setting.

John Allan, MD, an expert on chronic lymphocytic leukemia, details adverse events seen with venetoclax and obinutuzumab.

An expert on chronic lymphocytic leukemia reviews the CLL14 trial, evaluating venetoclax plus obinutuzumab in patients with previously untreated CLL.

An expert on chronic lymphocytic leukemia reviews the CLL14 trial, evaluating venetoclax plus obinutuzumab in patients with previously untreated CLL.

An expert hematologist-oncologist discusses the patient case and risk stratification for patients with newly diagnosed CLL.

John Allan, MD, presents the case of a 72-year-old woman with newly diagnosed chronic lymphocytic leukemia and shares his initial impressions.

John Allan, MD, speaks to the exciting future of treatments for chronic lymphocytic leukemia.

Dr John Allan discusses the adverse events he monitors for with select treatments for chronic lymphocytic leukemia, and when he decides to move to second-line therapy.

An expert in hematologic malignancies describes how he would monitor a patient on frontline treatment with newly diagnosed chronic lymphocytic leukemia.

John Allan, MD, explains how fitness level and comorbidities affect his treatment selections for chronic lymphocytic leukemia and whether he prefers fixed-duration or continuous-strategy approaches.

Dr John Allan gives an overview of the frontline treatment options available for chronic lymphocytic leukemia with reference to clinical trial data.

A leukemia expert discusses ongoing challenges in chronic lymphocytic leukemia treatment, and how to discuss risk stratification with a patient.

John Allan, MD, presents the case of a 70-year-old woman with newly diagnosed chronic lymphocytic leukemia.

John Allan, MD, looks to the future of chronic lymphocytic leukemia treatments.

An expert describes various treatment approaches for patients with high-risk chronic lymphocytic leukemia.

John Allan, MD, compares the available approved BTK inhibitors for treating chronic lymphocytic leukemia.

A leukemia specialist details the Resonate-2 clinical trial studying BTK inhibitor ibrutinib.

John Allan, MD, highlights treatment options in the first-line setting for chronic lymphocytic leukemia.

A key opinion leader shares insight into testing and risk stratification for chronic lymphocytic leukemia.

John Allan, MD, presents and reviews the case of a 67-year-old man with chronic lymphocytic leukemia.